VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

Search

Medtronic PLC

Slēgts

SektorsVeselības aprūpe

88.96 0.59

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

87.4

Max

88.97

Galvenie mērījumi

By Trading Economics

Ienākumi

32M

1.3B

Pārdošana

-111M

8.3B

P/E

Sektora vidējais

27.396

63.778

EPS

1.39

Dividenžu ienesīgums

3.12

Peļņas marža

15.798

Darbinieki

95,000

EBITDA

-40M

2.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+8.94% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.12%

2.39%

Nākamie ieņēmumi

2025. g. 22. maijs

Nākamais dividenžu datums

2025. g. 11. apr.

Nākamais Ex dividenžu datums

2025. g. 27. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-5.4B

115B

Iepriekšējā atvēršanas cena

88.37

Iepriekšējā slēgšanas cena

88.96

Ziņu noskaņojums

By Acuity

23%

77%

57 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Medtronic PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. febr. 12:24 UTC

Peļņas

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

2024. g. 19. nov. 12:27 UTC

Peļņas

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

2025. g. 27. febr. 10:30 UTC

Top Ziņas

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

2025. g. 18. febr. 11:47 UTC

Peļņas

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

2025. g. 18. febr. 11:46 UTC

Peļņas

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Adj EPS $1.39 >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Net $1.29B >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Diabetes Rev $694M >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Organic Revenue Up 4.1% >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q EPS $1.01 >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

2025. g. 18. febr. 11:45 UTC

Peļņas

Medtronic 3Q Sales $8.29B >MDT

2025. g. 18. febr. 10:01 UTC

Peļņas
Karstas akcijas

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

2025. g. 21. janv. 19:15 UTC

Top Ziņas

Medtronic Hires CFO From Renault -- Update

2025. g. 21. janv. 12:17 UTC

Top Ziņas

Medtronic Hires CFO From Renault

2024. g. 19. nov. 12:12 UTC

Peļņas

Medtronic Narrows FY Guidance as 2Q Tops Views

2024. g. 19. nov. 11:46 UTC

Peļņas

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

2024. g. 19. nov. 11:46 UTC

Peļņas

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Adj EPS $1.26 >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Diabetes Rev $686M >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Net $1.27B >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Organic Revenue Up 5.0% >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

2024. g. 19. nov. 11:45 UTC

Peļņas

Medtronic 2Q Sales $8.4B >MDT

Salīdzinājums

Cenas izmaiņa

Medtronic PLC Prognoze

Cenas mērķis

By TipRanks

8.94% augšup

Prognoze 12 mēnešiem

Vidējais 96.4 USD  8.94%

Augstākais 109 USD

Zemākais 85 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Medtronic PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

9

Pirkt

9

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

88.02 / 90.29Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

57 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.